Full Press Release Details
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company’s chief operating officer, will present at BIO CEO & Investor Conference on Monday, February 13, 2017 at 3:00 p.m. Eastern time. The conference is being held at the Waldorf Astoria in New York City on February 13-14, 2017.
A live webcast of the 25-minute presentation may be accessed on the conference’s website at http://www.veracast.com/webcasts/bio/ceoinvestor2017/86126440478.cfm with the ability to replay 1 hour after the conclusion of the webcast. The webcast and presentation will be archived for 90 days following the event on the company’s website at www.galectintherapeutics.com.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Tags
fibrotic liver disease
BIO CEO & Investor Conference